Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline Receptor Occupancy in Parkinson's Disease
NCT02933372Phase 2Completed
- Sponsor
- University of Michigan
- Start
- Oct 2015
- Primary completion
- Jun 2019
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of varenicline in Parkinson's disease (PD) (2 arms), sponsored by University of Michigan. Primary endpoint: Varenicline Occupancy of alpha4beta2* Nicotinic Acetylcholine Receptors at 15 days. Started Oct 2015; status: completed.
02
Drugs
varenicline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02933372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933372.